Stock fact sheet · data as of
Regeneron Pharmaceuticals, Inc. (REGN): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Blend
Is REGN undervalued?
Regeneron Pharmaceuticals, Inc. (REGN) closed at 778.36 on 16 Oct 2026, 16% above the GLS average fair value of 672.97. Only 3 of the 9 models that produced a number value the shares above the current price. The margin of safety is negative, so the stock fails the "below fair value" rule of the Sunday Scan; a premium of this size is common for companies whose growth the models are conservative about.
The 9 models disagree widely: DDM gives 54.44 while DCF gives 1,792.14. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files REGN under Blend.
Nine valuation models for REGN
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 1,792.14 | +130% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 537.47 | -31% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 1,026.48 | +32% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 346.98 | -55% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 222.63 | -71% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 896.61 | +15% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 714.83 | -8% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | 54.44 | -93% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | 465.15 | -40% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 84.70 | -89% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 856.25 | +10% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
On financial health REGN scores 7/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is 6.1 out of 10: a ten-year record that is consistent in some of the metrics the score tracks (revenue, earnings, margins, cash flow, returns on capital) and patchy in others.
Returns on capital are high - ROIC 13.3%, ROE 14.4%, ROA 11.1% - with debt at 0.09 times equity and a free-cash-flow yield of 4.4%.
The dividend yield is 0.48% with a payout ratio of 9% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from Collaboration Revenue 57%, Product 38%, Product and Service, Other 5% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 6/10 and Congressional trading 3/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | 13.3% |
|---|---|---|---|
| GLS Moat | 6.1 / 10 | ROE | 14.4% |
| Debt / equity | 0.09 | ROA | 11.1% |
| Free-cash-flow yield | 4.4% | Payout ratio | 9% |
| Institutions | 10 / 10 | Insiders · Congress | 6 · 3 / 10 |
Wheel Score 68: Good
REGN scores 68 out of 100 on the Wheel Score (Good band, 65-79). The score blends the margin of safety (Value, 6/25), Piotroski health (16/20), the GLS moat (9/15), the option premium on offer (20/20) and how easily the stock trades (18/20). Value (6/25) is the part holding the score back.
Implied volatility is 41% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 6,170 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 879k shares a day on a market cap of $80.1B, with a beta of 0.24 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 18 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 6 / 25 | -16% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 9 / 15 | moat 6.1/10 | |
| Premium | 20 / 20 | implied volatility 41% | |
| Stability | 18 / 20 | 879k shares/day, $80.1B cap, beta 0.24 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
Regeneron Pharmaceuticals, Inc. reports earnings on 28 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Regeneron Pharmaceuticals, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| MRNA Moderna, Inc. | 236.50 | - | - | 45Weak | $94.4B |
| ARGX argenx SE | 846.27 | 796.62 | -6% | 65Good | $52.3B |
| VRTX Vertex Pharmaceuticals Incorporated | 498.50 | 315.11 | -58% | 61Fair | $126.4B |
| RVMD Revolution Medicines, Inc. | 193.52 | 0.8792 | -21911% | 42Weak | $41.5B |
| ONC BeOne Medicines AG | 374.08 | 200.58 | -86% | 54Fair | $40.0B |
| ALNY Alnylam Pharmaceuticals, Inc. | 234.03 | 173.82 | -35% | 59Fair | $31.3B |
| ROIV Roivant Sciences Ltd. | 33.62 | 2.89 | -1063% | 44Weak | $24.3B |
| GMAB Genmab A/S | 37.82 | 44.48 | +15% | 73Good | $23.3B |
| UTHR United Therapeutics Corporation | 540.03 | 872.54 | +38% | 87Prime | $23.2B |
| INCY Incyte Corporation | 113.27 | 202.62 | +44% | 88Prime | $23.0B |
| BNTX BioNTech SE | 90.20 | 49.55 | -82% | 45Weak | $22.6B |
| INSM Insmed Incorporated | 99.21 | - | - | 45Weak | $21.7B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about REGN
Is REGN undervalued right now?
No: at 778.36 the stock trades 16% above the GLS average fair value of 672.97 (data as of 16 Oct 2026). The margin of safety is negative.
What is the Wheel Score of REGN and what does it mean?
REGN scores 68 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for REGN?
672.97 per share as of 16 Oct 2026 - the simple average of the 9 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Regeneron Pharmaceuticals, Inc. report earnings next?
The next earnings report is due on 28 Oct 2026 (before the open), 12 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does REGN have listed options, and how liquid are they?
Yes. The nightly snapshot found 1,000 listed contracts with 6,170 open interest across all expiries and implied volatility of 41% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.